AUPH
Aurinia Pharmaceuticals Inc.
$15.78
-0.81
(-4.88%)
Mkt Cap
2.03B
Volume
1,184,675
52W Range
8.55-19.25
Sector
Healthcare
Beta
1.42
EPS (TTM)
2.24
P/E Ratio
7.04
Revenue (TTM)
298.30M
Rev Growth (5Y)
+41.4%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$27.10
Undervalued
strong signal
41.8% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 283.06M | 235.13M | 175.51M | 134.03M | 45.60M | 50.12M | 318,000 | 463,000 | 420,000 | 173,000 | 235,000 | 278,000 |
| Net Income | 287.20M | 5.75M | (78.02M) | (108.18M) | (180.97M) | (102.68M) | (88.39M) | (64.12M) | (70.79M) | (23.30M) | (18.61M) | (16.65M) |
| EPS | 2.14 | 0.04 | -0.54 | -0.76 | -1.40 | -0.87 | -1.33 | -0.76 | -0.92 | -0.66 | -0.58 | -0.57 |
| Free Cash Flow | 135.41M | 44.11M | (34.18M) | (79.82M) | (159.19M) | (77.20M) | (63.69M) | (51.69M) | (41.19M) | (18.74M) | (17.82M) | (16.99M) |
| FCF / Share | 1.01 | 0.31 | -0.24 | -0.56 | -1.23 | -0.65 | -0.68 | -0.61 | -0.54 | -0.53 | -0.55 | -0.59 |
| Operating CF | 135.66M | 44.39M | (33.46M) | (79.53M) | (157.69M) | (69.86M) | (63.59M) | (51.61M) | (41.17M) | (18.71M) | (17.77M) | (16.90M) |
| Total Assets | 751.59M | 550.64M | 548.06M | 470.86M | 543.37M | 463.66M | 324.30M | 145.86M | 189.85M | 57.00M | 33.57M | 52.38M |
| Total Debt | 74.81M | 79.37M | 97.61M | 8.09M | 8.74M | 8.41M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 80.21M | 83.43M | 48.88M | 94.17M | 231.90M | 272.35M | 306.02M | 117.97M | 165.63M | 39.65M | 5.76M | 22.71M |
| Book Value | 581.33M | 377.48M | 377.95M | 405.44M | 479.09M | 407.75M | 298.60M | 112.58M | 165.74M | 35.95M | 19.96M | 45.11M |
| Return on Equity | 0.49 | 0.02 | -0.21 | -0.27 | -0.38 | -0.25 | -0.30 | -0.57 | -0.43 | -0.65 | -0.93 | -0.37 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.70M | 77.11M | 73.47M | 70.01M | 62.47M | 59.87M | 67.77M | 57.19M | 50.30M | 45.09M | 54.52M | 41.49M |
| Net Income | 34.35M | 210.79M | 31.55M | 21.51M | 23.34M | 1.43M | 14.35M | 722,000 | (10.75M) | (26.88M) | (13.45M) | (11.49M) |
| EPS | 0.26 | 1.58 | 0.24 | 0.16 | 0.16 | 0.01 | 0.10 | 0.01 | -0.07 | -0.19 | -0.09 | -0.08 |
| Free Cash Flow | 32.52M | 44.50M | 44.38M | 44.14M | 1.28M | 30.06M | 16.94M | 15.71M | (18.61M) | 14.25M | (13.17M) | (3.05M) |
| FCF / Share | 0.25 | 0.33 | 0.32 | 0.32 | 0.01 | 0.21 | 0.12 | 0.11 | -0.13 | 0.10 | -0.09 | -0.02 |
| Operating CF | 32.56M | 44.57M | 44.45M | 44.24M | 1.30M | 30.11M | 17.03M | 15.84M | (18.60M) | 14.31M | (13.28M) | (2.83M) |
| Total Assets | 724.00M | 751.59M | 527.53M | 502.56M | 504.85M | 550.64M | 549.36M | 523.53M | 516.63M | 548.06M | 555.01M | 548.90M |
| Total Debt | 68.64M | 74.81M | 78.21M | 81.83M | 77.91M | 79.37M | 87.85M | 85.98M | 88.54M | 97.61M | 93.21M | 101.21M |
| Cash & Equiv | 41.01M | 80.21M | 73.19M | 53.00M | 66.43M | 83.43M | 37.14M | 33.41M | 64.46M | 48.88M | 46.40M | 81.71M |
| Book Value | 567.63M | 581.33M | 365.77M | 335.30M | 350.19M | 377.48M | 388.00M | 364.62M | 359.48M | 377.95M | 391.88M | 392.29M |
| Return on Equity | 0.06 | 0.36 | 0.09 | 0.06 | 0.07 | 0.00 | 0.04 | 0.00 | -0.03 | -0.07 | -0.03 | -0.03 |
AUPH News
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript